Nautilus Biotechnology Joins ARPA-H Funded SEEDS Research Consortium
Nautilus Biotechnology has joined the SEEDS research consortium, which was awarded up to $51.7 million by ARPA-H to advance proteomics and disease research.
Stocks · News reference
Roth Capital Initiates Coverage On Nautilus Biotechnology with Buy Rating, Announces Price Target of $3.5
Roth Capital analyst Max Masucci initiates coverage on Nautilus Biotechnology (NASDAQ:NAUT) with a Buy rating and announces Price Target of $3.5.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Nautilus Biotechnology Reports Third Quarter 2026 Financial Results
Nautilus Biotechnology announced its financial results for the third quarter ended September 30, 2026, reporting a net loss of $15.6 million.
Nautilus to Measure Proteoforms Driving Alzheimer’s Disease and Cancer in ARPA-H-Funded SEEDS Consortium
Nautilus Biotechnology announced it will receive up to $6 million as part of a $51.7 million ARPA-H-funded SEEDS consortium led by Buck Institute and Georgetown University. The consortium aims to predict protein misfolding and develop diagnostics and therapeutics for neurodegenerative diseases and cancer. Nautilus will deploy its Voyager Platform to measure proteoforms in Alzheimer's disease and Ewing sarcoma research.
8-K filing — Nautilus Biotechnology, Inc. (NAUT)
Filed: 2026-10-27 AccNo: 0001808805-26-000049 Size: 266 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits